Karyopharm Therapeutics Inc. 8K

Karyopharm Therapeutics reported Q2 2026 results, reaffirmed 2026 guidance, advanced toward an August sNDA filing for selinexor plus ruxolitinib in myelofibrosis, and warned that without new financing or lender relief it may default on a senior secured term loan covenant following a $15.8 million payment due September 10, 2026.

On August 13, 2026, Karyopharm Therapeutics Inc. reported its second quarter 2026 financial results, reaffirmed full-year 2026 revenue guidance, and provided a strategic and regulatory update highlighting its planned August supplemental New Drug Application submission under the FDA’s Accelerated Approval pathway for selinexor in combination with ruxolitinib for myelofibrosis, while also disclosing liquidity constraints and a potential covenant default risk tied to a $15.8 million senior secured term loan payment due September 10, 2026 absent additional financing or lender relief. The company reported Q2 2026 total revenue of $33.4 million (including $30.8 million in U.S. XPOVIO net product revenue), an operating loss of $22.5 million, and a net loss of $67.0 million, driven in part by higher interest expense and significant non‑cash other expense related to derivative and warrant liabilities. Management outlined a pivot in R&D prioritization toward myelofibrosis and multiple myeloma following a Phase 3 endometrial cancer trial that failed to meet its primary endpoint, and noted that, together with financial advisor Centerview Partners and other advisors, it is actively evaluating financing opportunities and strategic alternatives to extend its cash runway beyond September 2026 and maximize stakeholder value. The company stated that, based on current plans, existing liquidity of $65.4 million in cash, cash equivalents, restricted cash and investments as of June 30, 2026, plus anticipated cash flows, will fund operations only into September 2026 and that making the September 10 term loan principal payment without new capital or a waiver would cause cash to fall below its $10 million minimum liquidity covenant, constituting an event of default under its senior secured term loan facility.

Filing Facts

CIK

1503802

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-347897

Alert Tier

8